<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="20801" end="20809" sStart="20718" offset="83" sid="r8.suggest.v.0137" wn="3" wnkey="suggest%2:32:02::" text="However, the failure to maintain the resistant virus on subsequent passage suggests that the pathogenicity of 14-P4 may have been only partially attenuated relative to the sensitive virus and indeed the pathogenicity of the clonal virus isolate, 14-P4E, was severely attenuated." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11062" end="11067" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" text="50 ?g/ml) and to ACV (results not &lt;b&gt;shown&lt;/b&gt;) according to the standard resistance breakpoint criteria, whereas isolates from mice treated with VCV had PCV IC 50 s ranging from 0.31-8." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="17502" end="17508" sStart="null" offset="131" sid="r11.severe.j.0340" wn="1" wnkey="severe%5:00:00:intense:00" text="Isolate 14-P4 containing 45% resistant virus caused significant clinical disease in mice, only marginally less severe than that observed with HSV-1 SC16." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11606" end="11616" sStart="null" offset="158" sid="r10.particular.j.0207" wn="2" wnkey="particular%5:00:02:specific:00" text="Generally, test sample IC 50 s varied within two-fold of the non-passaged control virus IC 50 , within each particular assay (data not shown); however, isolate 14-P4 was clearly different, with an IC 50 greater than 11-fold over the control virus IC 50 for both PCV and ACV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="4553" end="4559" sStart="null" offset="55" sid="r8.number.n.0113" wn="8" wnkey="number%1:10:02::" text="The ears from one mouse were pooled (passage number 1 inoculation) and used to inoculate the ear pinnae of one mouse (passage number 2)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11754" end="11758" sStart="null" offset="306" sid="r9.fold.v.0034" wn="2147483646" wnkey="null" text="Generally, test sample IC 50 s varied within two-fold of the non-passaged control virus IC 50 , within each particular assay (data not shown); however, isolate 14-P4 was clearly different, with an IC 50 greater than 11-fold over the control virus IC 50 for both PCV and ACV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11754" end="11758" sStart="null" offset="306" sid="r9.fold.v.0034" wn="2147483646" wnkey="null" text="Generally, test sample IC 50 s varied within two-fold of the non-passaged control virus IC 50 , within each particular assay (data not shown); however, isolate 14-P4 was clearly different, with an IC 50 greater than 11-fold over the control virus IC 50 for both PCV and ACV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="14106" end="14110" sStart="null" offset="469" sid="r9.fold.v.0600" wn="2147483645" wnkey="null" text="Generally, the proportion of PCV rvirus varied only two-fold between tests when compared to the control virus, ranging from 0.004 to 0.009% (data not shown); however, three serial samples in the VCV-treatment group, 14-P2, 14-P3 and 14-P4, clearly showed a substantial increase in the proportion of resistant virus relative to the wild type control, specifically an 11-, 300- and 8800-fold increase, respectively (14-P2, 0.002%; 14-P3, 2%; and 14-P4, 44% PCV r)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11754" end="11758" sStart="null" offset="306" sid="r9.fold.v.0034" wn="2147483645" wnkey="null" text="Generally, test sample IC 50 s varied within two-fold of the non-passaged control virus IC 50 , within each particular assay (data not shown); however, isolate 14-P4 was clearly different, with an IC 50 greater than 11-fold over the control virus IC 50 for both PCV and ACV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="11754" end="11758" sStart="null" offset="306" sid="r9.fold.v.0034" wn="" wnkey="null" text="Generally, test sample IC 50 s varied within two-fold of the non-passaged control virus IC 50 , within each particular assay (data not shown); however, isolate 14-P4 was clearly different, with an IC 50 greater than 11-fold over the control virus IC 50 for both PCV and ACV." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="16853" end="16859" sStart="null" offset="198" sid="r10.common.j.0294" wn="2" wnkey="common%3:00:01::" text="Sequence analysis of the TK coding region from all five plaque isolates identified a G nucleotide insertion in the homopolymeric hot-spot G7 tract at nucleotide 435, a common mutation present in other ACV rHSV isolates [ 18 19 ] . This base insertion produced a frame shift in the coding sequence, resulting in a loss of the ATP / nucleoside-binding site and the creation of a premature stop codon at amino acid 228 to encode a truncated 28 kD TK polypeptide." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2334-1-24.anc" start="1533" end="1539" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" text="After four serial passages in the immunocompetent mice, the infection &lt;b&gt;became&lt;/b&gt; completely refractory to ACV treatment." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="7348" end="7355" sStart="null" offset="149" sid="r11.absence.n.0625" wn="1" wnkey="absence%1:26:00::" text="The mutation frequency was calculated as follows: mutation frequency = (virus titer in the presence of drug)/(virus titer in the absence of drug)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="6967" end="6974" sStart="null" offset="181" sid="r11.absence.n.0848" wn="1" wnkey="absence%1:26:00::" text="with minor modifications [ 13 ] as reported previously [ 17 ] . Briefly, six serial 10-fold dilutions of virus were inoculated onto MRC-5 cells in the absence of antiviral drug or in the presence of either ACV or PCV at a concentration of antiviral 10 times higher than the average IC 50 for wild type parental HSV-1 and HSV-2, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-1-24.anc" start="19979" end="19986" sStart="null" offset="324" sid="r11.absence.n.0735" wn="1" wnkey="absence%1:26:00::" text="This mutation has also been detected in clinical isolates from patients immunocompromised [ 12 ] or with AIDS [ 19 ] as well as resistant HSV selected in tissue culture [ 15 18 ] . Interestingly, this mutation was present in ACV rclinical isolates obtained during reactivation in the absence of drug pressure, as well as in ACV rstrains which evolved during ACV therapy and were followed by ACV-susceptible isolates at the next reactivation [ 19 ] ." />
  </sentences>
</list>